Related Experiment Video

Updated: Aug 8, 2026

Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis
10:52

Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis

Published on: December 18, 2010

Reversible panhypogammaglobulinemia associated with phenytoin treatment

Luis F Pereira1, Juan F Sanchez

  • 1Laboratorio de Inmunologia, Hospital San Pedro de Alcantara, Cáceres, Spain. 927230289@telefonica.net

Scandinavian Journal of Infectious Diseases
|December 13, 2002
PubMed

Insights

Phenytoin treatment can cause panhypogammaglobulinemia and low B cell counts, leading to recurrent otitis. Monitor lymphocyte subpopulations and immunoglobulin levels if immunodeficiency symptoms arise during phenytoin therapy.

Area of Science:

  • Immunology
  • Pharmacology
  • Clinical Medicine

Background:

  • Phenytoin is an anticonvulsant medication commonly prescribed for epilepsy.
  • Immunodeficiency can manifest as recurrent infections, particularly otitis media.
  • Panhypogammaglobulinemia is a condition characterized by low levels of all major types of antibodies.

Observation:

  • A 24-year-old woman experienced recurrent otitis episodes.
  • Her condition was associated with panhypogammaglobulinemia and significantly reduced mature CD19+ B cells (84 cells/microl).
  • These hematological findings were linked to her phenytoin treatment.

Findings:

  • The patient's presentation suggests a potential adverse effect of phenytoin on B cell development and immunoglobulin production.
  • Low B cell counts and panhypogammaglobulinemia directly correlate with the patient's recurrent infections.
  • This case highlights a specific drug-induced immunodeficiency linked to phenytoin.

Implications:

  • Clinicians should consider monitoring lymphocyte subpopulations and immunoglobulin levels in patients initiating phenytoin treatment, especially if they develop symptoms of immunodeficiency.
  • Early detection and intervention are crucial to manage drug-induced immunodeficiencies and prevent severe infections.
  • This case underscores the importance of pharmacovigilance for anticonvulsant medications and their impact on the immune system.

More Related Videos

Induction of Experimental Autoimmune Hypophysitis in SJL Mice10:38

Induction of Experimental Autoimmune Hypophysitis in SJL Mice

Published on: December 18, 2010

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

Related Concept Videos

Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...